This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Phathom Pharmaceuticals (PHAT) and Zimmer Biomet Holdings (ZBH)

Tipranks - Tipranks - Sat May 2, 5:48AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amgen (AMGN), Phathom Pharmaceuticals (PHAT) and Zimmer Biomet Holdings (ZBH).

Claim 55% Off TipRanks

Amgen (AMGN)

In a report released today, Geoff Meacham from Citi maintained a Hold rating on Amgen, with a price target of $345.00. The company’s shares closed last Thursday at $346.25, close to its 52-week high of $346.85.

According to TipRanks.com, Meacham is a 5-star analyst with an average return of 9.4% and a 56.2% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals Inc, Protagonist Therapeutics, and Kiniksa Pharmaceuticals. ;'>

Currently, the analyst consensus on Amgen is a Moderate Buy with an average price target of $364.35, implying a 6.9% upside from current levels. In a report issued on April 20, Canaccord Genuity also initiated coverage with a Hold rating on the stock with a $366.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Phathom Pharmaceuticals (PHAT)

In a report released today, Matthew Caufield from H.C. Wainwright reiterated a Buy rating on Phathom Pharmaceuticals, with a price target of $26.00. The company’s shares closed last Thursday at $11.20.

According to TipRanks.com, Caufield is a 4-star analyst with an average return of 12.1% and a 42.4% success rate. Caufield covers the Healthcare sector, focusing on stocks such as Mineralys Therapeutics, Inc., 4D Molecular Therapeutics, and Tarsus Pharmaceuticals. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Phathom Pharmaceuticals with a $24.25 average price target, representing an 111.6% upside. In a report issued on April 28, Craig-Hallum also maintained a Buy rating on the stock.

Zimmer Biomet Holdings (ZBH)

In a report released today, Travis Steed from Bank of America Securities maintained a Hold rating on Zimmer Biomet Holdings, with a price target of $100.00. The company’s shares closed last Thursday at $82.43.

According to TipRanks.com, Steed is a 2-star analyst with an average return of 0.2% and a 47.3% success rate. Steed covers the Healthcare sector, focusing on stocks such as Kestra Medical Technologies Ltd., Bausch + Lomb Corporation, and Solventum Corporation. ;'>

The word on The Street in general, suggests a Hold analyst consensus rating for Zimmer Biomet Holdings with a $96.19 average price target, implying a 19.2% upside from current levels. In a report issued on April 24, Canaccord Genuity also maintained a Hold rating on the stock with a $93.00 price target.

Read More on AMGN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).